Table 1 |
|||
|
Baseline characteristics of the study groups: Japanese data |
|||
| Tocilizumab |
|||
|
|
|||
| Characteristic |
Placebo |
4 mg/kg |
8 mg/kg |
|
|
|||
| n |
53 |
54 |
55 |
| Age (years) |
53 |
54 |
56 |
| Sex (male/female) |
14/39 |
14/40 |
9/46 |
| RA duration (years) |
8.4 |
7.3 |
8.3 |
| Previous DMARD use |
5 |
4 |
5 |
| Tender joint count |
18 ± 8 |
19 ± 9 |
18 ± 10 |
| Swollen joint count |
14 ± 6 |
16 ± 9 |
14 ± 7 |
| ESR (mm/hour) |
69 ± 31 |
71 ± 29 |
67 ± 31 |
| CRP (mg/dl) |
5.5 ± 4.2 |
4.7 ± 2.9 |
4.5 ± 3.3 |
|
|
|||
|
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis. Adapted, with permission, from [12]. |
|||
|
Smolen and Maini Arthritis Research & Therapy 2006 8(Suppl 2):S5 doi:10.1186/ar1969 |
|||